EGFR and non-small cell lung carcinoma: In conclusion, our findings elucidate the metastatic patterns and type of EGFR mutations associated with the clinical outcomes of first-line OSI therapy and suggest that distinct progression patterns dependent on the type of EGFR mutation may be important in determining the treatment strategies in patients with EGFR-mutant NSCLC.